Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 500 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefoxitin sodium, quantity: 2.103 g - injection, powder for - excipient ingredients: - cefoxitin sodium for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology): peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, and skin and skin structure infections. cefoxitin sodium for injection has a high degree of stability against beta-lactamase and therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin sodium can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes or anaerobes. cefoxitin sodium for injection is also indicated for the prevention of post-operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefoxitin sodium, quantity: 1.051 g - injection, powder for - excipient ingredients: - cefoxitin sodium for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology): peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, and skin and skin structure infections. cefoxitin sodium for injection has a high degree of stability against beta-lactamase and therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin sodium can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes or anaerobes. cefoxitin sodium for injection is also indicated for the prevention of post-operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - darunavir, quantity: 400 mg - tablet, film coated - excipient ingredients: sodium chloride; hyprolose; macrogol 4000; titanium dioxide; crospovidone; polacrilin potassium; iron oxide red; colloidal anhydrous silica; iron oxide yellow; purified talc; silicified microcrystalline cellulose; polyvinyl alcohol; magnesium stearate - adult patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients,darunavir juno (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: sodium chloride; citric acid monohydrate; sodium citrate; water for injections - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; sodium citrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: water for injections; sodium citrate; citric acid monohydrate; sodium chloride - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium citrate; water for injections; sodium chloride; citric acid monohydrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - metaraminol tartrate, quantity: 4.744 mg (equivalent: metaraminol, qty 2.5 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections; dilute hydrochloric acid - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia,adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. ,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.